Genmab Reports 50% Reduction in Risk of Death in Phase 3 Trial
Genmab reported positive topline results from a Phase 3 head and neck cancer trial, including a 50% reduction in risk of death.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.